Effects of canagliflozin with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c disease duration and treatment intensity: results from the CANVAS program
Diabetologia. 2021;64:2402–14 doi.org/10.1007/s00125-021-05524-1
Data from two multicentre, double-blind, placebo-controlled trials (CANVAS and CANVAS-R) were used to evaluate the effects of canagliflozin on CV and kidney outcomes over a range of T2DM complexities versus placebo. Diabetes complexity was defined separately by baseline intensity of treatment, duration of diabetes and HbA1c.